On the evening of September 13, the first press conference of Beijing Zhongguancun Comprehensive Bonded Zone (hereinafter referred to as "Zhongguancun Comprehensive Bonded Zone") was held at the "Haidian Night" event site of the 2024 China International Fair for Trade in Services. Feng Bin, deputy director of Beijing Customs, announced that Fanzhi International Pharmaceutical (Beijing) Co., Ltd., a subsidiary of Beijing Fanzhi Medical Technology Co., Ltd., has successfully completed the customs clearance of goods exported into the zone, becoming the first export order in the history of Zhongguancun Comprehensive Bonded Zone. This marks the official opening of the Zhongguancun Comprehensive Bonded Zone and the entry into the substantive operation stage, which is an important step on the road of building a high-level open platform and promoting high-quality development, and will attract more international enterprises and projects to settle down.
As a subsidiary of Fanzhi Group, Fanzhi International leads international R&D management, strengthens brand going overseas, and at the same time more effectively undertakes the central sector of overseas market business in more than 30 countries, faces the international market, continues to strengthen Fanzhi's brand internationalization strategy, accelerates the promotion of the multi-center strategy from the initial overseas layout to Europe and the United States, and promotes the company's self-developed first-class intelligent rapid testing instruments, chips and reagent products to the global market to a larger extent. AI medical equipment, rapid detection chips, and various rapid diagnostic reagent products have been strengthened in the international market, and the basic medical system has been continuously promoted to upgrade intelligent, remote, digital, and grassroots, so that the public can enjoy more convenient basic medical products and services.
Song Keqing, the legal person of Beijing Fanzhi Medical Technology Co., Ltd., said: It is a great honor to become the first single customs clearance enterprise in Zhongguancun Comprehensive Bonded Zone. As a biomedical R&D enterprise, we have great business needs for policies such as tax exemption for imported equipment in the Comprehensive Bonded Zone, bonded R&D materials and parts, and verification of R&D finished products. Zhongguancun Comprehensive Bonded Zone will share a high-quality scientific research environment, perfect supporting facilities and preferential policy support for Fanzhi International, accelerate the process of international product research and development, and enhance technological innovation capabilities. In the future, Fanzhi Medical will rely on the advantages of the bonded R&D policy and the open innovation ecology of Zhongguancun Comprehensive Bonded Zone, actively expand the international and domestic markets, increase R&D efforts, explore cutting-edge scientific and technological fields with all parties, and continuously launch competitive innovation achievements to inject new vitality into regional economic development.
It is understood that Zhongguancun Comprehensive Bonded Zone is the country's first comprehensive bonded zone featuring "R&D and innovation" and "bonded R&D" as its main function, with the advantages of "four superposition" of the national service industry expansion and opening up comprehensive demonstration zone, free trade pilot zone, Zhongguancun national independent innovation demonstration zone and comprehensive bonded zone. In the next step, Zhongguancun Comprehensive Bonded Zone will take the opportunity of the first order of goods entering the zone to carry out institutional innovation stress tests such as linkage inside and outside the zone, create a "regulatory sandbox" for open policy innovation, empower enterprises to create competitive advantages with early trial and trial, win development opportunities with development and opening up, and help more Chinese enterprises strengthen their overseas strategy to become international brands.